AroCell Q2: An unrecognized fully financed growth case
Research Update
2023-08-28
14:50
Redeye emphasises that AroCell continues to go unnoticed by the stock market, with stable sales development, ongoing geographical expansion, and good cost control. Essentially, the Q2 financials were in line with our estimates, and we make only minor changes to our forecasts.
OB
Oscar Bergman
Disclosures and disclaimers